Risk of non-Hodgkin lymphoma and Kaposi's sarcoma in homosexual men

The Lancet ◽  
1990 ◽  
Vol 336 (8709) ◽  
pp. 248-249 ◽  
Author(s):  
CharlesS Rabkin ◽  
JamesJ Goedert
Author(s):  
Camila A Carlman ◽  
Bharat Mishra ◽  
Anita Patel

Human Immunodeficiency Virus (HIV) infection is both infectious and contagious disease. The people infected with HIV have an increased risk of cancer while comparing with uninfected people. Kaposi’s sarcoma, aggressive B-cell Non-Hodgkin Lymphoma & cervical cancer are the three types of cancers which are termed as “HIV –associated cancers”. Apart from these cancers, HIV patients are prone to cancers of anus, liver, lung, pharynx which are termed as “non-AIDS defining cancers”. Viral oncogenesis and cytokine induced growth contribute to the development of Kaposi sarcoma. Several virally encoded genes such as bcl-2, IL-6, cyclin-D, GPCR & interferon regulatory factor, plays key role in cellular proliferation and survival.  Infection with HIV weakens the immune system and reduces the body’s ability to fight against viral infections that may lead to cancer. Immunosuppression and inflammation in HIV patients also contribute to cancer progression. The complications of AIDS- related cancers include easy bleeding and bruising, tiredness, nausea, vomiting, poor appetite, mouth sores, hair loss etc. According to the data, HIV infected males are more susceptible to Kaposi’s sarcoma and Non- Hodgkin Lymphoma whereas females are more liable to cervical cancers. Early diagnosis and treatment options help to drop the risk of AIDS related cancers. The HAART therapy reduces the risk of cancer in HIV patients by lowering the amount of HIV circulating in blood, so that function of immune system to fight against the virus can be restored. Other treatment methods are chemotherapy, immunotherapy, radiation and surgery.


2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Peter D. Burbelo ◽  
Joseph A. Kovacs ◽  
Jason Wagner ◽  
Ahmad Bayat ◽  
Craig S. Rhodes ◽  
...  

Although HIV-positive patients are at higher risk for developing a variety of infection-related cancers, the prevalence of infections with the seven known cancer-associated viruses has not been studied. Luciferase immunoprecipitation systems were used to evaluate antiviral antibodies in four 23-person groups: healthy blood donors and HIV-infected patients with oral hairy leukoplakia (OLP), Kaposi's sarcoma (KS), or non-Hodgkin lymphoma (NHL). Antibody profiling revealed that all HIV-positive individuals were strongly seropositive for anti-gp41 and antireverse transcriptase antibodies. However, anti-p24 HIV antibody levels were highly variable and some OLP and KS patients demonstrated weak or negative responses. Profiling two EBV antigens revealed no statistical difference in antibody levels among the three HIV-infected groups. A high frequency of KSHV infection was detected in HIV patients including 100% of KS, 78% of OLP, and 57% of NHL patients. Most HIV-infected subjects (84%) showed anti-HBV core antibodies, but only a few showed antibodies against HCV. MCV seropositivity was also common (94%) in the HIV-infected individuals and KS patients showed statistically higher antibody levels compared to the OLP and NHL patients. Overall, 68% of the HIV-infected patients showed seropositivity with at least four cancer-associated viruses. Antibody profiles against these and other infectious agents could be useful for enhancing the clinical management of HIV patients.


The Lancet ◽  
1982 ◽  
Vol 319 (8281) ◽  
pp. 1083-1087 ◽  
Author(s):  
Michael Marmor ◽  
Linda Laubenstein ◽  
DanielC. William ◽  
AlvinE. Friedman-Kien ◽  
R.David Byrum ◽  
...  

1984 ◽  
Vol 132 (1) ◽  
pp. 195-195
Author(s):  
D.I. Abrams ◽  
E.K. Chinn ◽  
B.J. Lewis ◽  
P.A. Volberding ◽  
M.A. Conant ◽  
...  

1982 ◽  
Vol 68 (6) ◽  
pp. 537-542 ◽  
Author(s):  
Mario Cazzola ◽  
Gaetano Bergamaschi ◽  
Alessandro Castello ◽  
Corrado Del Forno ◽  
Laura Dezza ◽  
...  

Cutaneous and visceral dissemination of Kaposi's sarcoma (KS) occurred in a patient with angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) who had been treated with combination chemotherapy. Three other cases of KS complicating immunosuppressive therapy of AILD have been reported in the literature, and there is evidence to indicate that AILD displays features which are known to predispose to KS. Like in other subjects with profound immunodeficiency (e.g. in young homosexual men), in our patient KS pursued an unusually aggressive course, with involvement of lymph nodes and internal organs as well as the skin. It is concluded that the risk of developing severe KS is a further reason to avoid aggressive combination chemotherapy in patients with AILD, particularly in those of Jewish or Mediterranean ancestry. Even the use of corticosteroids should be reduced to a minimum to avoid immunosuppression, and a conservative approach to treatment seems advisable.


Sign in / Sign up

Export Citation Format

Share Document